Form 4: Spyre Therapeutics Directors Receive Stock Options
SEC Filing (Form 4)
Fairmount Funds Management LLC, along with directors Peter Harwin and Tomas Kiselak, report the acquisition of stock options in Spyre Therapeutics.
Summary
- Fairmount Funds Management LLC, Peter Harwin, and Tomas Kiselak filed a Form 4 with the SEC regarding changes in beneficial ownership of Spyre Therapeutics, Inc. [SYRE] securities.
- The filing indicates that Harwin and Kiselak each received stock options to purchase 11,323 shares of Spyre Therapeutics common stock on May 14, 2024, at an exercise price of $39.29 per share.
- The options vest in 12 equal monthly installments following the grant date, subject to continuous service with the issuer.
- Harwin and Kiselak hold these options on behalf of investment vehicles managed by Fairmount Funds Management LLC and disclaim beneficial ownership of the options and underlying common stock.
- Fairmount Funds Management LLC may be deemed a director by deputization because Harwin and Kiselak serve on the board of directors of the Issuer and are also each a Managing Member of the Adviser.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to stock option grants, which is a neutral event.
Industry Context
Stock options are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with those of shareholders.
Key Dates
| Date | Description |
|---|---|
| 05/14/2024 | Date of transaction (grant of stock options) |
| 05/14/2024 | Vesting start date for the stock options |
| 05/14/2034 | Expiration date of the stock options |
| 05/16/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.